These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24476998)

  • 1. Turning the Titanic.
    Zerhouni EA
    Sci Transl Med; 2014 Jan; 6(221):221ed2. PubMed ID: 24476998
    [No Abstract]   [Full Text] [Related]  

  • 2. Accelerating the pace of atherosclerosis research.
    Daugherty A; Tabas I; Rader DJ
    Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):11-2. PubMed ID: 25520521
    [No Abstract]   [Full Text] [Related]  

  • 3. The novel variant p.Ser465Leu in the PCSK9 gene does not account for the decreased LDLR activity in members of a FH family.
    Ruotolo A; Di Taranto MD; D'Agostino MN; Marotta G; Gentile M; Nunziata M; Sodano M; Di Noto R; Del Vecchio L; Rubba P; Fortunato G
    Clin Chem Lab Med; 2014 Aug; 52(8):e175-8. PubMed ID: 24607922
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetics: a gene of rare effect.
    Hall SS
    Nature; 2013 Apr; 496(7444):152-5. PubMed ID: 23579660
    [No Abstract]   [Full Text] [Related]  

  • 5. PCSK9: is it fluoride for cardiology?
    King SB
    JACC Cardiovasc Interv; 2014 Nov; 7(11):1331-2. PubMed ID: 25459045
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical use of genetic typing in human lipid disorders.
    Brown WV; Breslow J; Ballantyne C
    J Clin Lipidol; 2012; 6(3):199-207. PubMed ID: 22658144
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
    Lose JM; Dorsch MP; Bleske BE
    Pharmacotherapy; 2013 Apr; 33(4):447-60. PubMed ID: 23553812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent in vivo epigenetic silencing of Pcsk9.
    Gengaro IR; Qi LS
    Cell Res; 2024 Sep; 34(9):607-608. PubMed ID: 38565654
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of PCSK9: is this the way forward for managing residual risk?
    Chowdhury SR; Rees A
    Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999
    [No Abstract]   [Full Text] [Related]  

  • 10. The hunt for missing genes.
    Kaiser J
    Science; 2014 May; 344(6185):687-9. PubMed ID: 24833372
    [No Abstract]   [Full Text] [Related]  

  • 11. PCSK9 and its modulation.
    Cui CJ; Li S; Li JJ
    Clin Chim Acta; 2015 Feb; 440():79-86. PubMed ID: 25444750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihyperlipidemic therapies targeting PCSK9.
    Weinreich M; Frishman WH
    Cardiol Rev; 2014; 22(3):140-6. PubMed ID: 24407047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy and clinical trials.
    Sodhi N; Krasuski RA
    Curr Opin Lipidol; 2013 Jun; 24(3):281-2. PubMed ID: 23652475
    [No Abstract]   [Full Text] [Related]  

  • 14. Hyperlipidemia and cardiovascular disease: reinforcement for 'lower is better'.
    Burkhardt R
    Curr Opin Lipidol; 2015 Oct; 26(5):468-9. PubMed ID: 26339769
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulation of proprotein convertase subtilisin/kexin type 9: therapeutical perspectives.
    Chan DC
    Atherosclerosis; 2011 Jul; 217(1):77-9. PubMed ID: 21444085
    [No Abstract]   [Full Text] [Related]  

  • 16. Heart drug pushes outcome-based pricing plans.
    Senior M
    Nat Rev Drug Discov; 2015 Oct; 14(10):665-7. PubMed ID: 26424350
    [No Abstract]   [Full Text] [Related]  

  • 17. Winner by points?--LDL cholesterol as a target for therapeutic intervention.
    Tietge UJ
    Curr Opin Lipidol; 2013 Jun; 24(3):277-8. PubMed ID: 23652473
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promises of PCSK9 inhibition.
    Petrides F; Shearston K; Chatelais M; Guilbaud F; Meilhac O; Lambert G
    Curr Opin Lipidol; 2013 Aug; 24(4):307-12. PubMed ID: 23817198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9.
    Geschwindner S; Andersson GM; Beisel HG; Breuer S; Hallberg C; Kihlberg BM; Lindqvist AM; O'Mahony G; Plowright AT; Raubacher F; Knecht W
    Protein Eng Des Sel; 2015 May; 28(5):117-25. PubMed ID: 25744035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.